HK1199815A1 - Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation - Google Patents

Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation

Info

Publication number
HK1199815A1
HK1199815A1 HK15100262.4A HK15100262A HK1199815A1 HK 1199815 A1 HK1199815 A1 HK 1199815A1 HK 15100262 A HK15100262 A HK 15100262A HK 1199815 A1 HK1199815 A1 HK 1199815A1
Authority
HK
Hong Kong
Prior art keywords
levocetirizine
montelukast
influenza
inflammation
treatment
Prior art date
Application number
HK15100262.4A
Other languages
English (en)
Chinese (zh)
Inventor
Bruce Chandler
Original Assignee
Inflammatory Response Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammatory Response Res Inc filed Critical Inflammatory Response Res Inc
Publication of HK1199815A1 publication Critical patent/HK1199815A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15100262.4A 2010-06-16 2013-10-17 Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation HK1199815A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35552010P 2010-06-16 2010-06-16

Publications (1)

Publication Number Publication Date
HK1199815A1 true HK1199815A1 (en) 2015-07-24

Family

ID=45348536

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100262.4A HK1199815A1 (en) 2010-06-16 2013-10-17 Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation

Country Status (11)

Country Link
US (5) US9044479B2 (de)
EP (2) EP2582373A4 (de)
JP (2) JP5781606B2 (de)
KR (2) KR20130050952A (de)
CN (2) CN107308161A (de)
AU (1) AU2011268342B2 (de)
CA (1) CA2802853C (de)
ES (1) ES2705244T3 (de)
HK (1) HK1199815A1 (de)
MX (2) MX352824B (de)
WO (1) WO2011159821A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
IN2015KN00414A (de) 2012-08-21 2015-07-17 Sanofi Sa
RU2015134422A (ru) * 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении васкулита
EP3300734B1 (de) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Verwendung von levocetirizin und montelukast zur behandlung von autoimmunerkrankungen
CA2901411A1 (en) * 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of anaphylaxis
MX2015012315A (es) 2013-03-13 2015-12-16 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
WO2019004776A2 (en) * 2017-06-30 2019-01-03 Hanmi Pharm. Co., Ltd. COMPRESSED COMPOSITE CHEMICAL COMPRISING LEOVETITIZINE AND MONTELUKAST WITH IMPROVED STABILITY AND MEDICATION OBSERVANCE, AND PROCESS FOR PREPARING THE SAME
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
KR102481517B1 (ko) * 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
WO2023091107A1 (en) * 2021-11-22 2023-05-25 Istanbul Medipol Universitesi Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19
US20230190734A1 (en) * 2021-12-16 2023-06-22 IRR, Inc. Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP1208851A3 (de) 1991-11-14 2003-05-07 Alliance Pharmaceutical Corporation Medikament zur pulmonaren Verabreichung
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
CA2278152A1 (en) 1997-01-24 1998-07-30 Ahmad Al-Sabbagh Treatment of autoimmune disease using tolerization in combination with methotrexate
MY121744A (en) 1997-12-23 2006-02-28 Schering Corp Composition for treating respiratory and skin dieseases, comprising at least one leukotriene antogonist and at least one antihistamine.
AU2470299A (en) 1998-01-27 1999-08-09 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
MXPA03000848A (es) * 2000-07-28 2004-12-13 Immupharm Aps Metodos para el tratamiento de sintomas del resfriado comun, rinitis alergica e infecciones relacionadas con el tracto respiratorio.
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
PL206069B1 (pl) * 2001-06-28 2010-06-30 Ucb Farchim Sa Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę
US20050176687A1 (en) 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
DE50312523D1 (de) 2002-05-24 2010-04-29 Carl-Fr Coester Pharmazeutische wirkstoffkombination sowie deren verwendung
US7291331B1 (en) * 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2518409A1 (en) 2003-03-12 2004-09-23 John P. Mullally Composition and method for treating inflammations by reducing c-reactive protein
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20060110387A1 (en) 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
FR2881823B1 (fr) 2005-02-08 2007-03-16 Siemens Vdo Automotive Sas Utilisation de la magneto-impedance sur un capteur de position sans contact et capteur correspondant
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
PT2098248E (pt) 2005-12-21 2012-08-27 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos, glucocorticóides e agonistas de beta 2 para o tratamento de doenças inflamatórias
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
EP2559434A3 (de) 2007-02-12 2013-05-29 Mike Nicolaou Behandlung von COPD mit einem Histidine Decarboxylase Inhibitor allein oder kombiniert mit einer anti-H1 Verbindung oder mit einem Leucotriene Rezeptor Antagonist
EP2129683A4 (de) 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von herzinsuffizienz und anderen erkrankungen
KR20100059836A (ko) 2007-08-15 2010-06-04 케마지스 리미티드 고순도 레보세티리진 및 이의 염을 제조하기 위한 신규한 방법
WO2009052625A1 (en) 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
MX2010004563A (es) 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
CN102414196A (zh) 2009-03-02 2012-04-11 基因里克斯(英国)有限公司 改进的方法
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
KR20120123691A (ko) 2010-01-28 2012-11-09 머크 샤프 앤드 돔 코포레이션 통증 및 기타의 적응증의 치료를 위한 제약 조성물
KR20130050952A (ko) * 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2012013566A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
WO2012092594A2 (en) 2010-12-30 2012-07-05 Harish Ziv M D Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
EP2696849A4 (de) 2011-04-13 2014-10-29 Revalesio Corp Zusammensetzungen und verfahren zur hemmung und/oder modulation von effektor-zellen in entzündlichen neurodegenerativen erkrankungen
EP2520292A1 (de) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung von Spirangienen zur Behandlung oder Prävention von IL-8- oder IL-6-vermittelten Erkrankungen
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
US20150322049A1 (en) 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
EP3300734B1 (de) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Verwendung von levocetirizin und montelukast zur behandlung von autoimmunerkrankungen
CA2901411A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of anaphylaxis
RU2015134422A (ru) 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении васкулита
MX2015012315A (es) 2013-03-13 2015-12-16 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions

Also Published As

Publication number Publication date
US9044479B2 (en) 2015-06-02
MX352824B (es) 2017-12-11
KR20150038736A (ko) 2015-04-08
CN107308161A (zh) 2017-11-03
US20160175301A1 (en) 2016-06-23
EP2582373A4 (de) 2013-10-30
AU2011268342A1 (en) 2013-01-31
US20200323843A1 (en) 2020-10-15
EP2582373A1 (de) 2013-04-24
EP2799071A1 (de) 2014-11-05
MX2012014521A (es) 2013-05-20
US20190298714A1 (en) 2019-10-03
JP5781606B2 (ja) 2015-09-24
ES2705244T3 (es) 2019-03-22
EP2799071B1 (de) 2018-10-17
JP2013528654A (ja) 2013-07-11
AU2011268342B2 (en) 2014-12-04
CN103002896A (zh) 2013-03-27
US10537568B2 (en) 2020-01-21
CA2802853C (en) 2016-07-26
WO2011159821A1 (en) 2011-12-22
US20130085124A1 (en) 2013-04-04
JP2015180701A (ja) 2015-10-15
KR101801864B1 (ko) 2017-11-27
CA2802853A1 (en) 2011-12-22
KR20130050952A (ko) 2013-05-16
US20150231133A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
HK1199815A1 (en) Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation
HK1245130A1 (zh) 酶組合物及其用於創傷愈合的用途
HRP20181364T8 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
HRP20151041T1 (hr) Šprica i spremnik s dvostrukom komorom i šprica napunjena aripiprazolom
EP2651496A4 (de) Vorrichtungen, systeme und verfahren zur behandlung medizinischer erkrankungen
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2866830A4 (de) Anti-cxcl9-, anti-cxcl10-, anti-cxcl11-, anti-cxcl13-, anti-cxcr3- und anti-cxcr5-wirkstoffe zur hemmung von entzündungen
IL236226A0 (en) Medicinal or prophylactic agent for mild cognitive impairment
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1188565A1 (en) Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans
GB201117269D0 (en) Peptoids for the phrophlyactic and therapeutic clearance of bacteria
AU2012903508A0 (en) Breast-protective orthosis and use thereof
AU2012901404A0 (en) Patient registration and consent kiosk
GB201116165D0 (en) Metatronia therapy-a healing modality, using the eneriges and connections of archangel metatron
AU2010901717A0 (en) Cold treatment